Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current Deffered RevenueOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aclaris Therapeutics (ACRS) Non-Current Deffered Revenue (2024 - 2025)

Aclaris Therapeutics (ACRS) has 2 years of Non-Current Deffered Revenue data on record, last reported at $16.2 million in Q4 2025.

  • For Q4 2025, Non-Current Deffered Revenue fell 19.31% year-over-year to $16.2 million; the TTM value through Dec 2025 reached $16.2 million, down 19.31%, while the annual FY2025 figure was $16.2 million, 19.31% down from the prior year.
  • Non-Current Deffered Revenue reached $16.2 million in Q4 2025 per ACRS's latest filing, down from $17.5 million in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $21.2 million in Q3 2024 and bottomed at $16.2 million in Q4 2025.